NASDAQ:NBIXNeurocrine Biosciences Stock Price, Forecast & News

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBIX shares have increased by 45.3% and is now trading at $124.80. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurocrine Biosciences.

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Neurocrine Biosciences.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Wednesday, May, 6th. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm earned $237.10 million during the quarter, compared to analysts' expectations of $226.29 million. Neurocrine Biosciences had a net margin of 19.90% and a return on equity of 37.53%. The business's quarterly revenue was up 71.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.29 EPS. View Neurocrine Biosciences' earnings history.

15 equities research analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their forecasts range from $88.00 to $153.00. On average, they expect Neurocrine Biosciences' share price to reach $117.20 in the next year. This suggests that the stock has a possible downside of 6.1%. View analysts' price targets for Neurocrine Biosciences.

Headlines about NBIX stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutNeurocrine Biosciences.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), Trade Desk (TTD), salesforce.com (CRM) and Walt Disney (DIS).

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (8.22%), Capital International Investors (6.48%), Perceptive Advisors LLC (3.30%), Orbimed Advisors LLC (1.24%), Alliancebernstein L.P. (1.22%) and Geode Capital Management LLC (1.16%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View institutional ownership trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Alliancebernstein L.P., Nuveen Asset Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., and Voloridge Investment Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin. View insider buying and selling activity for Neurocrine Biosciences.

NBIX stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc., Janus Henderson Group PLC, Orbimed Advisors LLC, DSM Capital Partners LLC, Capital International Investors, Jennison Associates LLC, and GW&K Investment Management LLC. View insider buying and selling activity for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $124.80.

Neurocrine Biosciences has a market capitalization of $11.59 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.

The official website for Neurocrine Biosciences is www.neurocrine.com.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]